OrbiMed Capital GP VII LLC — SEC Form 4 filings
SEC reporting owner CIK 1760648. 22 Form 4 filings on record with FilingPulse; latest filed 2026-06-24.
Transaction summary — filings shown
Covers all 22 filings on record, filed 2024-02-14 to 2026-06-24. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 8 legs across 3 filings — 2,815,672 shares, $29,020,756 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 41 legs across 15 filings — 4,448,652 shares, $87,137,787 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 27.
- Largest priced transaction: sale of 787,024 shares @ $45.38 ($35,715,149) in Enliven Therapeutics, Inc., filed 2026-06-24.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | 10% owner | 3 | — | 8 legs · 2,174,831 sh · $74,560,296 | — |
| Q32 Bio Inc. (QTTB) | Director, 10% owner | 1 | 2 legs · 1,875,000 sh · $15,000,000 | — | — |
| MBX Biosciences, Inc. (MBX) | Director, 10% owner | 2 | 6 legs · 940,672 sh · $14,020,756 | — | 5 |
| Keros Therapeutics, Inc. (KROS) | Director | 2 | — | 2 legs · 250,000 sh · $11,002,500 | 2 |
| Passage BIO, Inc. (PASG) | 10% owner | 10 | — | 25 legs · 1,967,657 sh · $1,013,351 | — |
| Terns Pharmaceuticals, Inc. (TERN) | Director, 10% owner | 1 | — | 6 legs · 56,164 sh · $561,640 | — |
| Lomond Therapeutics Holdings, Inc. | Director | 1 | — | — | 13 |
| Kinnate Biopharma Inc. (KNTE) | Director, 10% owner | 1 | — | — | 5 |
| Theseus Pharmaceuticals, Inc. (THRX) | Director, 10% owner | 1 | — | — | 2 |
Form 4 filings — OrbiMed Capital GP VII LLC
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-24 | 4 | Enliven Therapeutics, Inc. (ELVN) jointly with ORBIMED ADVISORS LLC, OrbiMed Genesis GP LLC | Sale (S): 24,846 @ $45.38 · Sale (S): 1,477 @ $45 · Sale (S): 787,024 @ $45.38 · Sale (S): 46,776 @ $45 | EDGAR |
| 2026-06-17 | 4 | Enliven Therapeutics, Inc. (ELVN) jointly with ORBIMED ADVISORS LLC, OrbiMed Genesis GP LLC | Sale (S): 9,086 @ $45.02 · Sale (S): 272,322 @ $45.02 | EDGAR |
| 2026-06-01 | 4 | Q32 Bio Inc. (QTTB) jointly with ORBIMED ADVISORS LLC, OrbiMed Genesis GP LLC | Purchase (P): 1,250,000 @ $8 · Purchase (P): 625,000 @ $8 | EDGAR |
| 2025-12-18 | 4 | Keros Therapeutics, Inc. (KROS) jointly with ORBIMED ADVISORS LLC, OrbiMed Genesis GP LLC | Disposition to issuer (D): 140,057 @ $17.75 · Disposition to issuer (D): 74,465 @ $17.75 | EDGAR |
| 2025-06-26 | 4 | Passage BIO, Inc. (PASG) jointly with ORBIMED ADVISORS LLC | Sale (S): 231,600 @ $0.35 · Sale (S): 138,800 @ $0.33 · Sale (S): 213,257 @ $0.33 | EDGAR |
| 2025-04-24 | 4 | Passage BIO, Inc. (PASG) jointly with ORBIMED ADVISORS LLC | Sale (S): 78,049 @ $0.34 · Sale (S): 89,328 @ $0.34 · Sale (S): 68,195 @ $0.32 | EDGAR |
| 2025-04-17 | 4 | Passage BIO, Inc. (PASG) jointly with ORBIMED ADVISORS LLC | Sale (S): 10,326 @ $0.38 · Sale (S): 61,638 @ $0.33 · Sale (S): 77,090 @ $0.33 | EDGAR |
| 2025-02-19 | 4 | MBX Biosciences, Inc. (MBX) jointly with ORBIMED ADVISORS LLC, OrbiMed Genesis GP LLC | Purchase (P): 17,962 @ $9.90 · Purchase (P): 29,540 @ $9.85 · Purchase (P): 49,070 @ $10.84 · Purchase (P): 94,100 @ $10.84 | EDGAR |
| 2025-01-14 | 4 | Passage BIO, Inc. (PASG) jointly with ORBIMED ADVISORS LLC | Sale (S): 126,209 @ $0.66 · Sale (S): 17,986 @ $0.64 · Sale (S): 79,024 @ $0.60 | EDGAR |
| 2025-01-08 | 4 | Passage BIO, Inc. (PASG) jointly with ORBIMED ADVISORS LLC | Sale (S): 19,481 @ $0.77 · Sale (S): 52,536 @ $0.71 · Sale (S): 75,007 @ $0.68 | EDGAR |
| 2024-12-26 | 4 | Passage BIO, Inc. (PASG) jointly with ORBIMED ADVISORS LLC | Sale (S): 230,321 @ $0.60 | EDGAR |
| 2024-12-11 | 4 | Passage BIO, Inc. (PASG) jointly with ORBIMED ADVISORS LLC | Sale (S): 54,181 @ $0.84 · Sale (S): 8,015 @ $0.80 · Sale (S): 80 @ $0.80 | EDGAR |
| 2024-12-06 | 4 | Passage BIO, Inc. (PASG) jointly with ORBIMED ADVISORS LLC | Sale (S): 76,200 @ $0.79 · Sale (S): 20,903 @ $0.82 | EDGAR |
| 2024-11-05 | 4 | Lomond Therapeutics Holdings, Inc. jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP VIII LLC, OrbiMed Capital GP IX LLC | Conversion (C): 323,916 @ $3.20 · Conversion (C): 215,146 @ $3.20 · Conversion (C): 389,078 @ $3.60 · Conversion (C): 230,753 @ $3.60 · Conversion (C): 74,613 @ $3.60 · Grant/award (A): 808,894 @ $4 · +7 more | EDGAR |
| 2024-09-23 | 4 | Passage BIO, Inc. (PASG) jointly with ORBIMED ADVISORS LLC | Sale (S): 39,300 @ $0.71 | EDGAR |
| 2024-09-18 | 4 | Passage BIO, Inc. (PASG) jointly with ORBIMED ADVISORS LLC | Sale (S): 63,100 @ $0.74 · Sale (S): 111,400 @ $0.73 · Sale (S): 25,631 @ $0.73 | EDGAR |
| 2024-09-17 | 4 | MBX Biosciences, Inc. (MBX) jointly with ORBIMED ADVISORS LLC, OrbiMed Genesis GP LLC | Conversion (C): 2,658,428 · Conversion (C): 403,787 · Purchase (P): 500,000 @ $16 · Purchase (P): 250,000 @ $16 · Conversion (C): 12,372,634 (derivative) · Conversion (C): 19,587,284 (derivative) · +1 more | EDGAR |
| 2024-08-15 | 4 | Keros Therapeutics, Inc. (KROS) jointly with ORBIMED ADVISORS LLC, OrbiMed Genesis GP LLC | Sale (S): 220,600 @ $44.01 · Sale (S): 29,400 @ $44.01 | EDGAR |
| 2024-07-17 | 4 | Terns Pharmaceuticals, Inc. (TERN) jointly with ORBIMED ADVISORS LLC, OrbiMed Asia GP III, L.P., OrbiMed Advisors III Ltd, OrbiMed Genesis GP LLC | Sale (S): 39,433 @ $10 · Sale (S): 5,401 @ $10 · Sale (S): 6,142 @ $10 · Sale (S): 4,009 @ $10 · Sale (S): 556 @ $10 · Sale (S): 623 @ $10 | EDGAR |
| 2024-05-20 | 4 | Enliven Therapeutics, Inc. (ELVN) jointly with ORBIMED ADVISORS LLC, OrbiMed Genesis GP LLC | Sale (S): 33,300 @ $22.14 · Sale (S): 1,000,000 @ $22.14 | EDGAR |
| 2024-04-05 | 4 | Kinnate Biopharma Inc. (KNTE) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP VIII LLC, OrbiMed Asia GP IV, L.P., OrbiMed Advisors IV Ltd, OrbiMed Genesis GP LLC, ORBIMED CAPITAL LLC | Disposition to issuer (D): 1,368,339 · Disposition to issuer (D): 4,738,453 · Disposition to issuer (D): 1,368,338 · Disposition to issuer (D): 84,599 · Disposition to issuer (D): 450,000 | EDGAR |
| 2024-02-14 | 4 | Theseus Pharmaceuticals, Inc. (THRX) jointly with ORBIMED ADVISORS LLC, OrbiMed Genesis GP LLC | Code (U): 17,063,000 · Code (U): 650,600 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1760648 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →